Sunil Healthcare Ltd

Sunil Healthcare Ltd. has announced a special one-year window, from February 5, 2026, to February 4, 2027, for the transfer and dematerialisation of physical securities. This window is for investors who sold or purchased physical securities before April 1, 2019, and either failed to lodge them for transfer or had them rejected. Transferred securities will be mandatorily dematerialised and subject to a one-year lock-in period. Cases involving disputes or securities transferred to the Investor Education and Protection Fund (IEPF) are excluded. Shareholders are advised to submit necessary documents to the company's Registrar and Share Transfer Agent or the company directly.

Sunil Healthcare Ltd. has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in effect from July 01, 2026, and will remain until 48 hours after the declaration of the company's un-audited financial results for the first quarter of the financial year 2026-27, ending on June 30, 2026. The decision aligns with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct to prevent insider trading.

Sunil Healthcare Ltd's board meeting on May 29, 2026, approved the audited financial results (standalone and consolidated) for the year ended March 31, 2026. The board did not recommend any dividend for FY26. M/s. Agrawal S. Lal & Co. were appointed as Internal Auditors for FY27. Consolidated revenue from operations stood at ₹8,771.92 Lakhs for the year ended March 31, 2026.

Sunil Healthcare Ltd. has announced the approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors, in its meeting held on May 29, 2026, also noted the auditor's report with an unmodified opinion and did not recommend any dividend for the financial year 2025-26. Additionally, M/s. Agrawal S. Lal & Co. were appointed as Internal Auditors for the financial year 2026-27.

Sunil Healthcare Ltd approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board did not recommend any dividend for FY26. M/s. Agrawal S. Lal & Co., Chartered Accountants, Alwar, were appointed as Internal Auditors for FY27. Consolidated revenue from operations for the year ended March 31, 2026, stood at ₹8771.92 lakhs.

Sunil Healthcare Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the audited financial results (standalone and consolidated) for the fourth quarter and financial year ended March 31, 2026. The meeting will be held via video conferencing. The trading window remains closed from April 1, 2026, to May 31, 2026.

Sunil Healthcare Ltd. has announced the closure of the trading window for all designated persons and their immediate relatives, as per the Company's Code of Conduct, from April 01, 2026 till 48 hours after the declaration of Audited Financial results for the 4th quarter/Financial year 2025-26 ended on March 31, 2026. This decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015 and the amendments made in 2018.

Sunil Healthcare Ltd has approved the Un-Audited Financial Results for the 3rd quarter and nine months ended December 31, 2025. The Board Meeting was held on February 06, 2026. The financial results are prepared in accordance with the Indian Accounting Standard 34 and other accounting principles generally accepted in India.

Sunil Healthcare Ltd. board approved the unaudited financial results for the quarter and nine months ended 31st December 2025. The board meeting was held on 6th February 2026. The company prepared the financial statements in accordance with Ind AS 34 and other accounting principles generally accepted in India. The review report from Singhi & Co. Chartered Accountants states that nothing has come to their attention to cause them to believe that the financial statements contain any material misstatement.

Sunil Healthcare Ltd has announced that its Board of Directors will meet on February 06, 2026, to consider and approve the un-audited financial results for the quarter ended on December 31, 2025. The meeting will be held through video conferencing/audio visual connection as per SEBI regulations. The trading window will be closed from January 01, 2026, to February 08, 2026, under the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015.